Ventyx Biosciences

Ventyx Halts TYK2 Inhibitor Following Phase 2 Success

Ventyx Halts TYK2 Inhibitor Despite Phase 2 Success, Stock Plummets 70%

Anika Sharma

Ventyx Biosciences discovered that even a seemingly successful clinical trial may not be enough to support a drug’s advancement, as ...

Ventyx Biosciences, etrasimod, Zeposia (ozanimod), ulcerative colitis

Ventyx reports positive phase 2 data for bowel disease drug, but fails to impress investors amid competition

Anika Sharma

Investors have shown skepticism toward Ventyx Biosciences’ attempt to challenge Bristol Myers Squibb and Pfizer in the ulcerative colitis market. ...